Market Overview

UPDATE: Pfizer Posts Upbeat Q2 Results, Shares Gain

Related PFE
Pfizer Phase 3 Study Of Inotuzumab Ozogamicin Meets Primary Endpoint In Adult Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia
Global & Strategic Partners Initiate Phase III Study with Avelumab in Patients with Stage IIIb/IV Non-Small Cell Lung Cancer
Seeking Alpha's Biotech Weekly: Gilead Isn't Perfect, Biogen-Bass, Spring Fever, And More (Seeking Alpha)

Pfizer (NYSE: PFE) reported stronger-than-expected second-quarter results and cut its revenue forecast for the year.

Pfizer now expects revenue of $48.7 billion to $50.7 billion, versus its earlier forecast of $49.2 billion to $51.2 billion.

The New York-based company posted its quarterly earnings of $2.91 billion, or $0.45 per share, versus $14.1 billion, or $1.98 per share, in the year-ago quarter. Excluding special items, the company's earnings rose to $0.58 per share versus $0.56 per share.

Its revenue slipped 1.5% to $12.77 billion. However, analysts were expecting earnings of $0.57 per share on revenue of $12.47 billion.

Pfizer's research and development spending increased 13% to $1.71 billion.

Pfizer's revenue in global innovative pharmaceutical fell around 5%, while revenue in global established pharmaceutical declined about 6%. Revenue in the global vaccines unit rose 13%, while revenue in consumer health care units surged 14%. Revenue in global oncology unit jumped 16%.

Frank D'Amelio, Chief Financial Officer, said, “Overall, I am pleased with our second-quarter 2014 financial results despite the continued negative impact from product losses of exclusivity and the termination of certain co-promotion collaborations.”

Pfizer shares gained 1.26% to $30.48 in pre-market trading.

Posted-In: profitEarnings News Guidance


Related Articles (PFE)

Around the Web, We're Loving...